BioAge Labs Announces Closing of Initial Public Offering, Full …
RICHMOND, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (“BioAge”) (Nasdaq: BIOA), a clinical-stage biopharmaceutical company developing therapeutic product candidates for...
BioAge Labs Announces Closing of Initial Public Offering, Full …
Oct 1, 2024 · In addition to the shares sold in the initial public offering, BioAge today announced the closing on September 27, 2024 of its sale of 588,888 shares of its common stock at the initial public offering price per share in a concurrent private placement to an existing stockholder.
Exercise Benefit in a Pill: BioAge Labs Goes Public, Raising More …
Sep 26, 2024 · Following the IPO, BioAge plans to use about $140 million for the Phase 2 tests of azelaprag. IPO proceeds will also support manufacturing of the drug for planned Phase 3 studies.
Weight-loss drug developer BioAge raises $198 mln in U.S. IPO
Sep 26, 2024 · BioAge Labs has raised $198 million after pricing its upsized U.S. initial public offering at the midpoint of the targeted range at $18 per share, the weight-loss drug developer said on Wednesday.
Obesity drug developer BioAge seeks up to $587 mln valuation in US IPO
Sep 18, 2024 · Obesity-focused biotech BioAge Labs said on Wednesday it was seeking a valuation of as much as $587 million in its initial public offering in the United States, according to a regulatory...
BioAge Labs Files For $100M IPO, Becomes The New Entrant In …
Sep 4, 2024 · BioAge Labs Inc, a biotech focused on developing therapies for metabolic diseases, filed an SEC filing to raise up to $100 million in an initial public offering. The company was founded in 2015...
BioAge Labs IPO: stock price today in high-profile Nasdaq debut
Sep 26, 2024 · BioAge Labs IPO: Stock price will be closely watched today as the obesity drug developer debuts on the Nasdaq. The California-based biotech priced its shares at $18. Its lead product, a weight...
Eli Lilly partner BioAge files for US IPO | Reuters
Sept 3 (Reuters) - BioAge Labs, an obesity therapy-focused startup that has also collaborated with Eli Lilly (LLY.N), filed for an initial public offering in the United States on Tuesday as it...
Eli Lilly partner BioAge files for US IPO - Yahoo Finance
Sep 3, 2024 · (Reuters) -BioAge Labs, an obesity therapy-focused startup that has also collaborated with Eli Lilly, filed for an initial public offering in the United States on Tuesday as it looks to...
BioAge Labs Files for IPO to Be Led by Goldman, Morgan Stanley
Sep 3, 2024 · BioAge Labs Inc., a clinical-stage biotechnology company developing therapies for obesity and metabolic disease, has filed for an initial public offering. The company said Tuesday in a filing...